Lumida
/DMAC
⌘K
DiaMedica Therapeutics Inc

DiaMedica Therapeutics Inc

DMAC
$7.30USD↑+2.38%+0.17 today

MARKET CAP

393.3M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$7 – $8

52W RANGE

$4
$10

AI Summary

Stalk
TrimMedium

DMAC is in a Stage 4 decline despite a long-term uptrend, with a dominant lower high/low structure driving medium-term bearish bias. Price rallies have been rejected at declining EMAs and the 50-DMA, indicating supply control. A short-term uptick above EMAs reduces immediate sell timing, suggesting deferred execution. Trimming into resistance zones aligns with structural downtrend while awaiting clearer follow-through.

  • ↑Phase 2 preeclampsia trial interim shows on-target mechanistic response.
  • ↑Cash increased to $59.9 M, funding operations through 2027.
  • ↓Net cash used jumped to $29.1 M in FY 2025, cutting runway to Q3 2026.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

DiaMedica Therapeutics (NASDAQ: DMAC) is a clinical-stage biopharmaceutical company specializing in developing innovative treatments for significant unmet medical needs, particularly in areas like preeclampsia and acute ischemic stroke. The company focuses on leveraging its proprietary protein-based therapeutic platform, specifically DM199, to create disease-modifying therapies aimed at improving patient outcomes and addressing vascular pathologies. As an emerging player in a niche market with limited competition, DiaMedica seeks to position DM199 as a first-in-class therapeutic option.

Bull says

  • ↑Phase 2 preeclampsia trial interim shows on-target mechanistic response.
  • ↑Cash increased to $59.9 M, funding operations through 2027.
  • ↑Analyst consensus: Strong Buy with $15.50 PT implies 152% upside.
  • ↑Health Canada clearance for global Phase 2 boosts regulatory confidence.
  • ↑Planned U.S. entry expands addressable maternal-health market.
  • ↑Positive growth and momentum factors may drive investor interest.

Bear says

  • ↓Net cash used jumped to $29.1 M in FY 2025, cutting runway to Q3 2026.
  • ↓Site activation and patient enrollment lag risk delaying studies.
  • ↓Negative profitability and earnings yield signal low near-term returns.
  • ↓High leverage raises debt risk amid rising clinical expenses.
  • ↓Elevated short interest reflects bearish investor sentiment pressure.
  • ↓Emerging competitors heighten risk if DM199 fails to outperform.

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 04-27-2026bullish

Transcript signals

Bull points

  • Looking back for a moment, 2025 is a year in which we made significant progress across our pipeline, achieving a number of key milestones.
  • We believe that this mechanism is why DM-19 is so well-suited to improve patient outcomes for preeclampsia, fetal growth restriction, acute ischemic stroke, and other indications associated with vascular pathology.
  • This publication underscores the need for new treatment approaches to lower blood pressure in patients with chronic kidney disease.

Bear points

  • We will terminate the study for lack of efficacy.
  • Net cash used in operating activities for the full year 2025 was $29.1 million compared to $22.1 million for the full year of 2024. This increase is primarily a result of the increase to net loss for the full year of 2025 as compared to the prior year period.
Read full transcript analysis ›